Drug Trial Radar · NCT03966898
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
426
Planned (sponsor's estimate)
Start
Jul 19, 2019
Primary completion
Dec 30, 2022
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole in Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for this study.
Conditions
- Advanced Breast Cancer
Interventions
SHR6390 TabletsDrug
SHR6390 Tablets
Placebo TabletsDrug
Placebo Tablets
Letrozole or Anastrozole TabletsDrug
Letrozole or Anastrozole Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed PFSTime frame: Every 8 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, Up to approximately 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nayima Bayaxi
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.